Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Clinical Prediction, Diagnosis, and Treatment of Ovarian Cancer and Other...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Prediction, Diagnosis, and Treatment of Ovarian Cancer and Other Gynecologic Tumors

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 15 December 2025 | Viewed by 817

Special Issue Editors

Dr. Eleni T. Timotheadou

E-Mail Website
Guest Editor
Department of Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: gynecologic cancer; breast cancer; translational research; clinical trials
Dr. Emmanouil Saloustros

E-Mail Website
Guest Editor
Department of Oncology, University Hospital of Larissa, 41334 Larissa, Greece
Interests: breast cancer; hereditary cancer; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Ovarian cancer remains a diagnostic and therapeutic challenge in the area of gynecologic oncology. The majority of cases are high-grade tumors, usually diagnosed at an advanced stage. These patients undergo either primary or interval debulking, targeting ideally to radical surgery.

The induction of PARP inhibitors in the management of advanced platinum-responsive disease has improved outcomes in first- and second-line treatment; however, a number of patients fail to remain in PARP maintenance longer than a few months, while some present with de novo resistance.

Patients who fail to achieve a complete remission at the end of the initial line of therapy are at risk of early progression and poor response to further treatments.

Considering these, ovarian cancer leaves ample space for research, both basic and clinical.

More or less, this stands for the rest of the gynecological malignancies that have long been poorly understood and managed. Cervical and endometrial cancer are entering a new era where immunotherapy holds a growing part, together with upcoming novel agents.

In this Special Issue we welcome your work in original research, reviews, meta-analyses, case reports, or short letters in all chapters of gynecologic cancer management, including screening, diagnosis, and treatment.

Dr. Eleni T. Timotheadou
Dr. Emmanouil Saloustros
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian
  • endometrial
  • cervical
  • chemotherapy
  • immunotherapy
  • primary debulking surgery
  • interval debulking
  • fertility-sparing surgery
  • PARP inhibitors
  • radiotherapy
  • HIPEC
  • sex cord tumors
  • dysgerminoma
  • leiomyosarcoma
  • liquid biopsies
  • circulating tumor cells
  • ctDNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 231 KB  
Article
Utilization of Ligasure® Maryland Jaw Open Sealer/Divider with Nanocoating Improves Perioperative Parameters in Women with Advanced Ovarian Cancer Subjected to Cytoreductive Surgery
by Dimitrios Tsolakidis, Kimon Chatzistamatiou, Efthalia Markopoulou, Dimitrios Zouzoulas, Vasilis Theodoulidis, Panagiotis Tzitzis, Iliana Sofianou, Kalliopi Kissoudi, Maria Topalidou, Eleni Timotheadou and Grigorios Grimbizis
J. Clin. Med. 2025, 14(17), 6293; https://doi.org/10.3390/jcm14176293 - 5 Sep 2025
Viewed by 539
Abstract
Background/Objectives: Cytoreductive surgery for women with advanced ovarian cancer is a demanding process with high morbidity. The present analysis aims to identify whether using the Ligasure® Maryland jaw open sealer/divider (LMJsd) with a nanocoating (Covidien®, Medtronic®, 710 [...] Read more.
Background/Objectives: Cytoreductive surgery for women with advanced ovarian cancer is a demanding process with high morbidity. The present analysis aims to identify whether using the Ligasure® Maryland jaw open sealer/divider (LMJsd) with a nanocoating (Covidien®, Medtronic®, 710 Medtronic Parkway, Minneapolis, MN, USA), could lead to better outcomes during cytoreduction surgery by reducing intraoperative bleeding and other hospitalization-related parameters. Methods: Patients with ovarian cancer (FIGO III/IV) who were subjected to primary or interval cytoreductive surgery at the Gynecologic-Oncology Unit, 1st Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Thessaloniki, Greece, were included in the analysis. Patients were retrospectively allocated into two groups: women operated on with or without using the LMJsd. Differences between the two groups (intraoperative blood loss and blood transfusion, duration of surgery, postoperative blood transfusion, admission to intensive care unit (ICU), and overall hospital length of stay) were investigated. Results: From 2012 to 2020, 284 women with ovarian cancer were surgically treated; 208 were stage III/IV. In the LMJsd group of women (n = 34), the duration of surgery and blood loss during surgery were significantly decreased (p < 0.0005) compared to the non-LMJsd group (n = 174). The intraoperative blood transfusion rate and the number of packed red blood cell units transfused were significantly decreased in the first group (p = 0.0025); the postoperative blood transfusion rate was not different (p = 0.065). Moreover, ICU admission and overall hospital length of stay were significantly decreased in the LMJsd group (p < 0.0005 and p = 0.015). Conclusions: Using the LMJsd is associated with decreased intraoperative bleeding and transfusion rates, duration of surgery, admission to ICU, and overall hospital length of stay in women treated with surgical cytoreduction for advanced ovarian cancer. Some limitations of this study are as follows: its limited impact because it is an observational retrospective analysis and bias because the cumulative experience of the surgeons may have an impact on the surgical outcomes. Full article
(This article belongs to the Special Issue Clinical Prediction, Diagnosis, and Treatment of Ovarian Cancer and Other Gynecologic Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop